Related references
Note: Only part of the references are listed.CYP2B6 G516T Polymorphism but Not Rifampin Coadministration Influences Steady-State Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus-Infected Patients in South India
Geetha Ramachandran et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
CYP2B6 (c.516G→T) and CYP2A6 (*9B and/or*17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients
Awewura Kwara et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Pharmacogenetics-Based Population Pharmacokinetic Analysis of Efavirenz in HIV-1-Infected Individuals
M. Arab-Alameddine et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Discordance in HIV-1 viral loads and antiretroviral drug concentrations comparing semen and blood plasma
G. Lorello et al.
HIV MEDICINE (2009)
Associations between CYP2B6 Polymorphisms and Pharmacokinetics after a Single Dose of Nevirapine or Efavirenz in African Americans
David W. Haas et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function
Julia di Iulio et al.
PHARMACOGENETICS AND GENOMICS (2009)
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients
Christoph Wyen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Aberrant splicing caused by single nucleotide polymorphism c.516G> T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver
Marco H. Hofmann et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P4502B6*6 and*26
Hiroyuki Gatanaga et al.
CLINICAL INFECTIOUS DISEASES (2007)
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro
Zeruesenay Desta et al.
PHARMACOGENOMICS (2007)
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals
M. Rotger et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
JE Gallant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens
K Tsuchiya et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
The cytochrome P4502B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity
BA Ward et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
C Marzolini et al.
AIDS (2001)
Share Paper
